PROTEOS INC

Proteos Inc. specializes in the pilot-scale production and purification of complex viral envelope proteins for biomedical research, with demonstrated expertise in HIV-1 and HIV-2 glycoprotein constructs including P24-GP41 and P24_ENV GP41. The company applies advanced protein expression, folding, and purification methodologies to generate structurally authentic antigens critical for vaccine development, diagnostic assay calibration, and immunological studies. Their technical proficiency lies in recombinant protein engineering, chromatographic separation, and quality control of conformationally sensitive viral antigens—key requirements for infectious disease research and therapeutic discovery. This precision-focused approach positions them as a niche provider of biologically relevant protein reagents for high-stakes virology applications. Proteos Inc. has delivered services to the Department of Health and Human Services, specifically supporting HIV research initiatives through the production of clinically relevant viral antigens. Their engagement reflects a focused partnership in advancing virological reagent development, likely supporting NIH-funded programs or CDC-led surveillance and vaccine efforts. The nature of the work suggests a trusted, project-specific relationship centered on technical execution rather than broad institutional contracting. The contractor’s primary NAICS classification under 541990 indicates a specialization in other professional, scientific, and technical services—particularly in the biotechnology and life sciences support space. Their market positioning is defined by serving research-driven agencies requiring bespoke protein production, distinguishing them from generalist scientific service providers through their focus on structurally complex envelope glycoproteins. Proteos Inc. is a small, privately held entity based in Kalamazoo, Michigan, with no public certifications on record. Their operational footprint is narrowly concentrated in specialized protein manufacturing for federal biomedical research, aligning them with the niche ecosystem of government-funded infectious disease R&D.